139 related articles for article (PubMed ID: 36031050)
1. Targeting tumor-associated MUC1 overcomes anoikis-resistance in pancreatic cancer.
Bose M; Sanders A; De C; Zhou R; Lala P; Shwartz S; Mitra B; Brouwer C; Mukherjee P
Transl Res; 2023 Mar; 253():41-56. PubMed ID: 36031050
[TBL] [Abstract][Full Text] [Related]
2. A novel association of neuropilin-1 and MUC1 in pancreatic ductal adenocarcinoma: role in induction of VEGF signaling and angiogenesis.
Zhou R; Curry JM; Roy LD; Grover P; Haider J; Moore LJ; Wu ST; Kamesh A; Yazdanifar M; Ahrens WA; Leung T; Mukherjee P
Oncogene; 2016 Oct; 35(43):5608-5618. PubMed ID: 26804176
[TBL] [Abstract][Full Text] [Related]
3. Overcoming Immunological Resistance Enhances the Efficacy of A Novel Anti-tMUC1-CAR T Cell Treatment against Pancreatic Ductal Adenocarcinoma.
Yazdanifar M; Zhou R; Grover P; Williams C; Bose M; Moore LJ; Wu ST; Maher J; Dreau D; Mukherjee AP
Cells; 2019 Sep; 8(9):. PubMed ID: 31514488
[TBL] [Abstract][Full Text] [Related]
4. Treatment of pancreatic ductal adenocarcinoma with tumor antigen specific-targeted delivery of paclitaxel loaded PLGA nanoparticles.
Wu ST; Fowler AJ; Garmon CB; Fessler AB; Ogle JD; Grover KR; Allen BC; Williams CD; Zhou R; Yazdanifar M; Ogle CA; Mukherjee P
BMC Cancer; 2018 Apr; 18(1):457. PubMed ID: 29685122
[TBL] [Abstract][Full Text] [Related]
5. Combining the Specific Anti-MUC1 Antibody TAB004 and Lip-MSA-IL-2 Limits Pancreatic Cancer Progression in Immune Competent Murine Models of Pancreatic Ductal Adenocarcinoma.
Dréau D; Moore LJ; Wu M; Roy LD; Dillion L; Porter T; Puri R; Momin N; Wittrup KD; Mukherjee P
Front Oncol; 2019; 9():330. PubMed ID: 31114758
[TBL] [Abstract][Full Text] [Related]
6. Early detection of pancreatic cancer in mouse models using a novel antibody, TAB004.
Wu ST; Williams CD; Grover PA; Moore LJ; Mukherjee P
PLoS One; 2018; 13(2):e0193260. PubMed ID: 29462213
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis.
Besmer DM; Curry JM; Roy LD; Tinder TL; Sahraei M; Schettini J; Hwang SI; Lee YY; Gendler SJ; Mukherjee P
Cancer Res; 2011 Jul; 71(13):4432-42. PubMed ID: 21558393
[TBL] [Abstract][Full Text] [Related]
8. CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth.
Zhou R; Yazdanifar M; Roy LD; Whilding LM; Gavrill A; Maher J; Mukherjee P
Front Immunol; 2019; 10():1149. PubMed ID: 31178870
[TBL] [Abstract][Full Text] [Related]
9. Mucin 1 Regulates Cox-2 Gene in Pancreatic Cancer.
Nath S; Roy LD; Grover P; Rao S; Mukherjee P
Pancreas; 2015 Aug; 44(6):909-17. PubMed ID: 26035123
[TBL] [Abstract][Full Text] [Related]
10. MUC1 regulates PDGFA expression during pancreatic cancer progression.
Sahraei M; Roy LD; Curry JM; Teresa TL; Nath S; Besmer D; Kidiyoor A; Dalia R; Gendler SJ; Mukherjee P
Oncogene; 2012 Nov; 31(47):4935-45. PubMed ID: 22266848
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of an
Kelly VJ; Wu ST; Gottumukkala V; Coelho R; Palmer K; Nair S; Erick T; Puri R; Ilovich O; Mukherjee P
Theranostics; 2020; 10(15):6946-6958. PubMed ID: 32550914
[No Abstract] [Full Text] [Related]
12. Activation of Vitamin D/VDR Signaling Reverses Gemcitabine Resistance of Pancreatic Cancer Cells Through Inhibition of MUC1 Expression.
Wei D; Wang L; Liu Y; Hafley MA; Tan L; Lorenzi PL; Yang P; Zuo X; Bresalier RS
Dig Dis Sci; 2023 Jul; 68(7):3043-3058. PubMed ID: 37071246
[TBL] [Abstract][Full Text] [Related]
13. MUC1 extracellular domain confers resistance of epithelial cancer cells to anoikis.
Zhao Q; Piyush T; Chen C; Hollingsworth MA; Hilkens J; Rhodes JM; Yu LG
Cell Death Dis; 2014 Oct; 5(10):e1438. PubMed ID: 25275599
[TBL] [Abstract][Full Text] [Related]
14. A Novel Monoclonal Antibody Targets Mucin1 and Attenuates Growth in Pancreatic Cancer Model.
Wu G; Maharjan S; Kim D; Kim JN; Park BK; Koh H; Moon K; Lee Y; Kwon HJ
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 29987260
[TBL] [Abstract][Full Text] [Related]
15. MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition.
Roy LD; Sahraei M; Subramani DB; Besmer D; Nath S; Tinder TL; Bajaj E; Shanmugam K; Lee YY; Hwang SI; Gendler SJ; Mukherjee P
Oncogene; 2011 Mar; 30(12):1449-59. PubMed ID: 21102519
[TBL] [Abstract][Full Text] [Related]
16. MUC1 Promoter-Driven DTA as a Targeted Therapeutic Strategy against Pancreatic Cancer.
Tholey RM; Lal S; Jimbo M; Burkhart RA; Blanco FF; Cozzitorto JA; Eisenberg JD; Jiang W; Iacobuzio-Donahue CA; Witkiewicz AK; Glbert M; Yeo CJ; Brody JR; Sawicki JA; Winter JM
Mol Cancer Res; 2015 Mar; 13(3):439-48. PubMed ID: 25336517
[TBL] [Abstract][Full Text] [Related]
17. Galectin-3 regulates MUC1 and EGFR cellular distribution and EGFR downstream pathways in pancreatic cancer cells.
Merlin J; Stechly L; de Beaucé S; Monté D; Leteurtre E; van Seuningen I; Huet G; Pigny P
Oncogene; 2011 Jun; 30(22):2514-25. PubMed ID: 21258405
[TBL] [Abstract][Full Text] [Related]
18. Hepatocyte growth factor inhibits anoikis of pancreatic carcinoma cells through phosphatidylinositol 3-kinase pathway.
Watanabe S; Kishimoto T; Yokosuka O
Pancreas; 2011 May; 40(4):608-14. PubMed ID: 21499215
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of HMGA1 promotes anoikis resistance and constitutive Akt activation in pancreatic adenocarcinoma cells.
Liau SS; Jazag A; Ito K; Whang EE
Br J Cancer; 2007 Mar; 96(6):993-1000. PubMed ID: 17342093
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of MUC1 Induces Non-Canonical TGF-β Signaling in Pancreatic Ductal Adenocarcinoma.
Bose M; Grover P; Sanders AJ; Zhou R; Ahmad M; Shwartz S; Lala P; Nath S; Yazdanifar M; Brouwer C; Mukherjee P
Front Cell Dev Biol; 2022; 10():821875. PubMed ID: 35237602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
